首页> 外文会议>St. Gallen EORTC Gastrointestinal Cancer Conference >Rectal Cancer with Synchronous Liver Metastases: Leave It All in? When (not) to Resect the Primary?
【24h】

Rectal Cancer with Synchronous Liver Metastases: Leave It All in? When (not) to Resect the Primary?

机译:与同步肝转转移的直肠癌:留在一切?什么时候(不是)攻击主要?

获取原文

摘要

Rectal cancer with synchronous distant metastases is challenging the choice of optimal treatment. Today, it is unknown if and when the primary tumor should or should not be resected. The current literature was reviewed. Data on the safety of a primary chemotherapy approach are reported. These publications indicate that at least in selected situations without severe symptoms or complications resulting from the primary, the rectum can be left in situ without major risks for the patient. However, retrospective analyses from randomized controlled trials indicate a potential prognostic advantage for patients having the primary tumor resected. The reason for this observation is largely unknown and requires further investigation. Due to the lack of data from prospective randomized controlled trials illuminating the situation of rectal cancer with synchronous distant metastases and due to the rapid changes evolving in the field of systemic treatment of metastatic colorectal cancer, no clear conclusions can be drawn at this stage. But a practical algorithm that may reflect current European treatment patterns is presented in this article.
机译:具有同步远距离转移的直肠癌是挑战最佳治疗的选择。今天,如果原发性肿瘤应该或不应该切除,则未知。综述了目前的文献。报道了关于初级化疗方法的安全性的数据。这些出版物表明,至少在没有严重的症状或主要症状的情况下的情况下,直肠可以留在原位上,没有患者的主要风险。然而,来自随机对照试验的回顾性分析表明患者切除患者的潜在预后优势。这种观察的原因在很大程度上是未知的,需要进一步调查。由于缺乏来自前瞻性随机对照试验的数据,照明直肠癌与同步远离转移的情况,并且由于在转移结直肠癌的全身治疗领域的发展领域的快速变化,可以在这个阶段抽出明确的结论。但是,本文提出了一种可能反映当前欧洲治疗模式的实用算法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号